Phase II, randomized, multicentric, clinical trial of a therapeutic vaccination, with ex vivo generated autologous Dentritic Cells pulsed with HIV lipopetides, combined or not with a TLR-3 agonist (poly-ICLC, Hiltonol), in the control of viral replication following antiretroviral treatment interruption in HIV-1 infected patients
Latest Information Update: 28 Dec 2020
At a glance
- Drugs HIV vaccine (Primary) ; HIV vaccine (Primary) ; Poly ICLC (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 28 Dec 2020 New trial record